Careers
Contact Us
Navigate Adaptimmune Limited
Home
Our Company
Overview
Board of Directors
Management & Founders
Partners
Pipeline
Overview
MAGE-A10
MAGE-A4
AFP
NY-ESO
Technology
Overview
The Immune System
Our Engineered T-Cell Therapies
Our Technology Platform
Manufacturing
Intellectual Property
Publications
Patients & Families
Overview
Our Clinical Trials
Clinical Trial FAQ
Cancer Information
NEW
Cancer Immunotherapy Month
News & Events
News
Scientific Conferences
Investor Conferences
Investors
Focusing on the needs of our patients
Learn More
Enhancing the Affinity of T-cell to Fight Cancer
Learn More
Investigating SPEAR T-Cell Therapy in 10 Solid Tumors
Learn More
Working with Leading Experts to Transform T-cell Therapy for Cancer Patients
Learn More
Latest News •
View all
September 7, 2018
Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
September 5, 2018
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
August 15, 2018
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
Adaptimmune on Linkedin
Adaptimmune on Twitter
Tweets by Adaptimmune
The Immune System
Clinical Trials
Our Pipeline
Manufacturing
Partnerships
